Amvuttra 25 mg/0.5 mL (Vutrisiran Vials) 25 mg/0.5 mL

Amvuttra 25 mg/0.5 mL is a prescription injectable solution for hereditary transthyretin-mediated amyloidosis. This vutrisiran therapy helps manage polyneuropathy symptoms in adults. Store below 25°C and protect from light. Consult a healthcare provider for suitability.

Strength

25 mg/0.5 mL

Pack Size

Storage

Below 25°C

Manufacturer / TM Owner

Alnylam Pharmaceuticals, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Amvuttro 25 mg/0.5 mL is used to treat hereditary transthyretin-mediated amyloidosis, a condition that affects nerves and organs. It is prescribed for adults with polyneuropathy symptoms to help manage disease progression. This medication is not a cure but may slow symptom worsening. It is given as an injection under medical supervision.

Side Effects

Amvuttro 25 mg/0.5 mL works by reducing abnormal transthyretin protein buildup in the body. Patients may notice improved nerve function and reduced pain over time. Some experience mild injection-site reactions like redness or swelling. Effects vary by individual and require consistent use.

Precautions & Warnings

Keep Amvuttro 25 mg/0.5 mL refrigerated or stored below 25°C as directed. Protect from light and avoid freezing. Do not use if the solution is discolored or contains particles. Always follow healthcare provider instructions for handling and disposal. Report any unusual symptoms immediately.

Avoid Interactions

Amvuttro 25 mg/0.5 mL may interact with other medications, including certain supplements and herbal products. Avoid alcohol during treatment unless approved by a doctor. Inform your healthcare provider about all drugs you are taking. No major food interactions are known, but discuss diet with your provider.

Frequently Asked Questions

Vutrisiran is used to treat hereditary transthyretin-mediated amyloidosis in adults, helping manage polyneuropathy symptoms.

It is given as an injection under medical supervision, typically every three months.

Common effects may include injection-site reactions like redness or swelling.

Store below 25°C and protect from light; do not freeze or expose to extreme heat.

It may interact with certain drugs; always inform your healthcare provider about all medications you take.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.